$NTRA

BOTHA ROELOF sold $2.2M of NTRA (indirect holdings)

BOTHA ROELOF sold 10,100 indirectly-held shares of Natera, Inc. (NTRA) at $219.78 ($2.22M total) on 2026-06-01.

Original reporting
SEC EDGAR · BOTHA ROELOF
Published Jun 3, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may briefly reassess sentiment around NTRA due to director selling, but there is no new operational/financial information in the filing.

02

Market read

A disclosed director sale at a specific price; potential minor sentiment effect only.

03

What to watch

The transaction is indirect and lacks stated rationale; without follow-on buys or company news, signal-to-noise is limited.

Relevance 6/10Novelty 6/10Timing: after-hours/filing timestamp (2026-06-03) for a 2026-06-01 sale

Background

This is an SEC Form 4 insider transaction disclosure (director sale) for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera director BOTHA ROELOF sold 10,100 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact is likely short-lived.

Evidence & confidence

The filing provides a concrete sale price/size, but insider transactions are often non-informational and the article contains no accompanying company-specific news.

Market effects

No sector-level read-through provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing rather than a bearish signal, especially without a 10b5-1 plan.

Key entities

  • Natera, Inc.

    Subject of the insider transaction disclosure; director sold shares via open-market sale.

  • BOTHA ROELOF

    Natera director who sold 10,100 shares at ~$219.7768/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.